IL155886A0 - Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings - Google Patents

Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Info

Publication number
IL155886A0
IL155886A0 IL15588601A IL15588601A IL155886A0 IL 155886 A0 IL155886 A0 IL 155886A0 IL 15588601 A IL15588601 A IL 15588601A IL 15588601 A IL15588601 A IL 15588601A IL 155886 A0 IL155886 A0 IL 155886A0
Authority
IL
Israel
Prior art keywords
factor vii
coagulation factor
activated coagulation
thrombolytic therapy
bleedings
Prior art date
Application number
IL15588601A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL155886A0 publication Critical patent/IL155886A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15588601A 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings IL155886A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
PCT/EP2001/015132 WO2002049665A2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
IL155886A0 true IL155886A0 (en) 2003-12-23

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15588601A IL155886A0 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Country Status (25)

Country Link
US (2) US20040087502A1 (pt)
EP (2) EP1216709A1 (pt)
JP (1) JP2004516273A (pt)
KR (1) KR20030063454A (pt)
CN (1) CN1482919A (pt)
AT (1) ATE353666T1 (pt)
AU (2) AU2002226386B2 (pt)
BR (1) BR0116151A (pt)
CA (1) CA2431986A1 (pt)
CY (1) CY1106363T1 (pt)
CZ (1) CZ300670B6 (pt)
DE (1) DE60126650T2 (pt)
DK (1) DK1343523T3 (pt)
EC (1) ECSP034647A (pt)
ES (1) ES2280429T3 (pt)
HU (1) HUP0302574A3 (pt)
IL (1) IL155886A0 (pt)
MX (1) MXPA03005641A (pt)
NZ (1) NZ549850A (pt)
PL (1) PL205878B1 (pt)
PT (1) PT1343523E (pt)
RU (1) RU2286796C2 (pt)
SI (1) SI1343523T1 (pt)
WO (1) WO2002049665A2 (pt)
ZA (1) ZA200304140B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006144397A (ru) * 2004-06-21 2008-07-27 Ново Нордиск Хелс Кеа Аг (Ch) ПРИМЕНЕНИЕ ФАКТОРА VIIa ИЛИ ЭКВИВАЛЕНТОВ ФАКТОРА VIIa ДЛЯ ПРЕДОТВРАЩЕНИЯ РАЗВИТИЯ КРОВОИЗЛИЯНИЯ И/ИЛИ ОТЕКА, ОБРАЗОВАННОГО В РЕЗУЛЬТАТЕ ВНУТРИМОЗГОВОГО КРОВОИЗЛИЯНИЯ
US20090156481A1 (en) * 2005-07-15 2009-06-18 Novo Nordisk Healthcare A/G Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
EP2244726A2 (en) 2008-01-18 2010-11-03 Novo Nordisk Health Care AG Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) in a selected subpopulation of ich patients
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
ATE353666T1 (de) 2007-03-15
ECSP034647A (es) 2003-07-25
EP1343523A2 (en) 2003-09-17
DE60126650D1 (de) 2007-03-29
WO2002049665A2 (en) 2002-06-27
HUP0302574A2 (hu) 2003-10-28
CZ20031743A3 (cs) 2003-11-12
EP1343523B1 (en) 2007-02-14
CN1482919A (zh) 2004-03-17
CA2431986A1 (en) 2002-06-27
NZ549850A (en) 2008-04-30
US20080286259A1 (en) 2008-11-20
AU2638602A (en) 2002-07-01
SI1343523T1 (sl) 2007-04-30
ES2280429T3 (es) 2007-09-16
HUP0302574A3 (en) 2010-01-28
BR0116151A (pt) 2003-10-21
RU2003122362A (ru) 2005-02-10
ZA200304140B (en) 2004-04-22
CZ300670B6 (cs) 2009-07-15
JP2004516273A (ja) 2004-06-03
AU2002226386B2 (en) 2005-12-22
CY1106363T1 (el) 2011-10-12
WO2002049665A3 (en) 2002-09-26
PL361855A1 (en) 2004-10-04
EP1216709A1 (en) 2002-06-26
KR20030063454A (ko) 2003-07-28
DK1343523T3 (da) 2007-04-10
US20040087502A1 (en) 2004-05-06
PT1343523E (pt) 2007-03-30
PL205878B1 (pl) 2010-06-30
MXPA03005641A (es) 2004-12-03
RU2286796C2 (ru) 2006-11-10
DE60126650T2 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
PT1039887E (pt) Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol
WO1997047296A3 (en) Compositions comprising vanadium compounds for use in the treatment of proliferative disorders and arthropathies
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2005027972A3 (en) Combination of a vegf receptor inhibitor with a chemotherapeutic agent
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
IL155886A0 (en) Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings
HRP20040383B1 (en) Non-neurotoxic plasminogen activating factors for treating stroke
CA2461117A1 (en) Botulinus toxin for treatment of body odour
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
MXPA03010743A (es) Uso de inhibidores de il-18 para el tratamiento o prevencion de lesiones del sistema nervioso central.
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
WO2004026252A3 (en) Glioma treatments
HK1054506A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees